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Common features of the solid tumor microenvironment, such as acidic extracellular pH and growth
factors, are known to induce the redistribution of lysosomes from a perinuclear region to a position near
the plasma membrane. Lysosome/plasma membrane juxtaposition facilitates invasion by allowing for the
release of lysosomal proteases, including cathepsin B, which contribute to matrix degradation. In this
study we identiﬁed the sirtuin 1/sirtuin 2 (SIRT1/2) inhibitor cambinol acts as a drug that inhibits ly-
sosome redistribution and tumor invasion. Treatment of cells with cambinol resulted in a juxtanuclear
lysosome aggregation (JLA) similar to that seen upon treatment with the PPARγ agonist, troglitazone
(Tro). Like Tro, cambinol required the activity of ERK1/2 in order to induce this lysosome clustering
phenotype. However, cambinol did not require the activity of Rab7, suggesting that this drug causes JLA
by a mechanism different from what is known for Tro. Additionally, cambinol-induced JLA was not a
result of autophagy induction. Further investigation revealed that cambinol triggered JLA independently
of its activity as a SIRT1/2 inhibitor, suggesting that this drug could have effects in addition to SIRT1/2
inhibition that could be developed into a novel anti-cancer therapy.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Metastatic disease accounts for 90% of cancer-associated
deaths. Invasion through the basement membrane allows tumor
cells to access sites beyond the tissue of origin which is a pre-
condition for metastasis. Although there are protease-independent
mechanisms of invasion, it is widely accepted that protease ac-
tivity greatly contributes to the invasive potential of tumor cells
[1,2]. Speciﬁcally, the release of lysosomal cathepsins and matrixB.V. This is an open access article u
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h Street, Lubbock, TX 79430,metalloproteinases are thought to contribute to tumor invasion by
promoting degradation of the extracellular matrix. Lysosomes are
acidic vesicles that normally function as degradative organelles at
the endpoint of the endosomal pathway and are rich in hydrolases
and proteases, including cathepsins B, D, and L. Several studies
have shown that cathepsin expression is enhanced in invasive
cancer cells and secreted cathepsin B can be found at sites of in-
vadopodia formation, supporting the notion that release of lyso-
some proteases promotes an invasive phenotype [3–7].
Lysosomes trafﬁc along microtubules and actin ﬁlaments via
the activity of ATP-dependent kinesin and dynein motor com-
plexes [8]. The position of lysosomes within cells can be inﬂuenced
by extracellular stimuli, resulting in anterograde (plus end) or
retrograde (minus end) trafﬁcking. Tumor cells with lysosomes
positioned closer to the plasma membrane secrete more proteases
and are more invasive when compared to cells with lysosomes
clustered near the center of the cell over the microtubule orga-
nizing center (MTOC) [9–13]. Several stimuli that are commonly
found within the extracellular tumor microenvironment, such as
growth factors and acidic pH, drive anterograde lysosomender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the extracellular pH (pHe) can reach as low as 6.0 as a result of
reduced blood ﬂow, enhanced sodium hydrogen exchanger (NHE)
activity, and anaerobic glycolysis (Warburg Effect) [15]. The acidic
pHe has been shown to enhance tumor invasiveness both in vitro
and in vivo [16,17]. Acidic pHe also stimulates anterograde lyso-
some trafﬁcking and previous studies have found that this lyso-
some redistribution is necessary for cathepsin B release and tumor
cell invasion in response to acidic pHe, which is mediated by NHE
activity [12]. We previously identiﬁed troglitazone (Tro), an anti-
diabetic PPARγ agonist, and ethyl-isopropyl amiloride (EIPA), an
NHE antagonist, as novel inhibitors of anterograde lysosome traf-
ﬁcking. Tro treatment induces a juxtanuclear lysosome aggrega-
tion (JLA) in an ERK/Rab7/RILP-dependent manner and inhibits
acidic pHe and growth factor-mediated tumor invasion [10].
Previous studies strongly suggest that inhibition of anterograde
lysosome trafﬁcking and protease release could be therapeutically
beneﬁcial to slow tumor invasion [10–13]. Due to clinical toxicity
associated with Tro treatment, we have begun to use a high-con-
tent imaging approach to screen for compounds that also prevent
anterograde lysosome trafﬁcking (manuscript in preparation). Our
collaborators previously characterized Sirtuin 1 (SIRT1), one of
seven class III histone deacetylase (HDAC), as a major contributor
to cancer cell migration and invasion [18,19]. Sirtuins are NADþ
dependent deacetylases, are the mammalian homologs of yeast
SIR2 (silent information regulator 2), and have many histone and
non-histone targets [20]. As sirtuins are often upregulated in
cancer, a number of inhibitors have been generated to facilitate the
study of the role of individual sirtuins in disease. Cambinol is a β-
naphthol compound that is thought to speciﬁcally inhibit the
deacetylase activity of SIRT1/2. It is well tolerated in mice and has
potent antitumor activity in vivo [21]. To assess the role of SIRT1/2
activity in cancer cell lines, our collaborators performed a micro-
array analysis to characterize the gene expression changes be-
tween control-treated and cambinol-treated cells (unpublished
data) and found that Rab7 mRNA was overexpressed in cambinol
treated cells. Rab7 is a small GTPase that speciﬁcally localizes to
lysosomes, recruits dynein motors to lysosomes via its effector
RILP, and drives JLA, resulting in decreased tumor invasion [11,22].
The upregulation of Rab7 in response to cambinol treatment
suggests that sirtuins may play a role in lysosome trafﬁcking. The
goal of this study was to determine the effects of cambinol treat-
ment on lysosome positioning. We found that cambinol was a
potent inhibitor of acidic pHe-mediated anterograde lysosome
trafﬁcking. In addition, we showed that the JLA phenotype occurs
independently of Rab7 or changes in gene expression, highlighting
the distinct differences in mechanism of action compared to Tro.
Additionally, we found that cambinol induces JLA independently of
its activity as a SIRT1/2 inhibitor, suggesting that cambinol may
have effects on other cellular targets. The ability to alter lysosmal
trafﬁcking makes cambinol a viable therapeutic agent for slowing
tumor progression.2. Materials and methods
2.1. Cell culture
The human prostate cancer cell lines DU145 ATCC (Manassas, Va)
and PPC1 (a generous gift from Dr. Brianna Williams, LSU-Health
Shreveport, originally obtained from Brothman [23]) were main-
tained in RPMI 1604 with 10% FBS and 1% Penicillin–Streptomycin.
The human glioma cell line A127 (ATCC) was maintained in DMEM
with 10% FBS and 1% Penicillin–Streptomycin. All cells were cultured
at 37 °C and 5% CO2 and passaged upon reaching 80% conﬂuence. For
experiments involving treatment with acidic media, cells weretreated with RPMI 1604 containing 130 mM NaCl and 10 mM
NaHCO3þ2% FBS. The pH was adjusted to 6.4 prior to the start of the
experiment. SIRT1 and NonTarget shRNA expressing cells were
maintained under 3.6 μg/mL Puromycin (Fisher, Waltham, MA).
2.2. Reagents and antibodies
Cambinol, Actinomycin D, TSA, Rapamycin, and Nicotinamide
were purchased from Sigma (St. Louis, MO). AK1 and AGK2 were
purchased from ChemBridge (San Diego, Ca). EX527 was supplied
by Selleck Chemicals (Houston, TX). UO126 was purchased from
Calbiochem (Billerica, MA) and used at 10 μM. LAMP-1 antibody
(h4A3) was obtained from the Developmental Studies Hybridoma
Bank at the University of Iowa and used at a 1:200 dilution. GM130
and EEA1 antibodies (BD Biosciences, San Jose, CA) were used at
1:50. Mitotracker Red (Molecular Probes, Carlsbad, CA) was used
according to the manufacturer's protocol. The SIRT1 (B-10) and Ac-
tubulin antibodies were purchased from Santa Cruz Biotechnology
(Dallas, TX) and was used at 1:1000. pMEK1/2 S271/221, p70 S6
Kinase Thr389, pErk1/2 T202/Y204, Ac-p53 Lys382, LC3I/II, and
total Erk1/2 antibodies (Cell Signaling Technology, Beverly, MA)
were used at 1:1000 for western blot. Anti-tubulin antibody
(NeoMarkers, Fremont, CA) was used at 1:100 for immuno-
ﬂuorescence (IF) and 1:20,000 for western blot analysis. Secondary
antibodies include Dylight 594 donkey anti-mouse 1:100 (Jackson
IR, West Grove, PA) for immunoﬂorescence, and HRP-conjugated
anti-mouse and anti-rabbit for western blot (GE Healthcare,
Pittsburgh, PA) used at 1:5000. Phalloidin 488 (Invitrogen, Carls-
bad, CA) was used at 1:200.
2.3. Immunoﬂuorescence
Cells were seeded at 50% conﬂuence on 22 mm coverslips in
6-well dishes. Following experimental treatment, cells were ﬁxed
in 4% PFA (pH 7.2) for 20 min at room temperature. Cells were then
washed once with Phosphate Buffered Saline (PBS) (Corning,
Manassas, VA) and then incubated with primary antibody for one
hour at room temperature in BSP (0.25% bovine serum albumin
and 0.1% Sapponin in PBS). Cells were washed twice with PBS then
incubated for 1 h with secondary antibody in BSP for one hour at
room temperature, protected from light. Cells were washed once
with PBS, and then incubated with phalloidin in BSP for 20 min at
room temperature protected from light. Cells were washed three
times with PBS and coverslips were mounted using DAPI with
SlowFade gold anti-fade reagent (Invitrogen). For LC3-GFP-
mCherry IF, cells were ﬁxed for 7 min in ice-cold methanol, wa-
shed with PBS, and coverslips were mounted using DAPI with slow
fade gold reagent. Images were taken on a 40 (Olympus UPlanFl
40 /0.75) or 60 (UPlan Apo 60 /0.90) objective using an
Olympus BX50 microscope, Roper Scientiﬁc Sensys Camera, and
MetaView software. Images were pseudocolored and merged
using ImageJ.
2.4. Western blot analysis
Cell lysates were harvested in boiling Laemmli buffer contain-
ing 2% β-mercaptoethanol and then boiled for ﬁve minutes. SDS-
PAGE was performed loading equal volume of each sample. Protein
was transferred to PVDF membrane, blocked in 5% milk in TBST
and incubated with the indicated antibodies overnight at 4 °C.
Anti-mouse or anti-rabbit HRP-conjugated secondary antibodies
(GE Healthcare) were diluted at 1:5000 in 5% milk TBST. Mem-
brane was developed using Pierce ECL 2 Western Blotting Sub-
strate (Thermo) and Premium Blue X-Ray Film (Phenix). Re-
presentative blots are shown.
Fig. 1. Cambinol induces juxtanuclear lysosome aggregation and atypical cytoskeleton organization. (A) DU145 prostate cancer cells were treated with (I) vehicle at pH
7.4 for 8 h, (II) vehicle at pH 7.4 for 6 h followed by a 2 h treatment at pH 6.4, or (III) 50 mM cambinol for 6 h in pH7.4 media followed by a 2 h treatment in pH 6.4 media in the
continued presence of drug. Cells were stained for LAMP-1 (red), Actin (green), or DAPI (blue) (N¼3). (B) Represents mean lysosome distribution for 25 cells spanning
3 independent experiments. Error bars represent SEM. *po0.0001 compared to II. (C) Cells were treated with 50 mM cambinol over time. Whole cell lysates were collected
and western blot analysis was performed. (D) DU145 cells were seeded on top of Transwell Inserts coated with a 1:10 dilution of Matrigel in the presence or absence of 50 mM
cambinol. Cells that invaded to the underside of the insert were stained with crystal violet and representative 10 images are shown. Graph represents quantitation from
three independent invasion assays. (E) Cells were treated with vehicle or 50 mM cambinol for 6 h at pH 7.4 followed by a 2 h incubation at pH 6.4 plus drug. Cells were then
ﬁxed and stained with anti-tubulin or phalloidin (N¼3). Scale bar represents 50 mm.
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Cells were pretreated with pH 6.4 buffered RPMI for 48 h prior
to the start of the invasion assay. Transwell inserts (Corning) with
an 8 mm pore were coated with 50 mL of a 1:10 dilution of Matrigel
(Corning, Corning, NY) in serum free media. Matrigel solidiﬁed for
30 min at 37°. 3104 cells were seeded on top of the Matrigel-
coated insert in a total volume of 100 mL serum free RPMI pH 6.4.
pH 6.4 buffered RPMI supplemented with 10% FBS was added to
the underside of the insert, and cells were allowed to invade for
24 h. Inserts were then ﬁxed with 4% PFA for 20 min and stained
with 0.1% crystal violet (SigmaAldrich) for 20 min. Cells andMatrigel remaining on the top of the insert were removed using a
cotton swab. Cells that had invaded to the underside of the insert
were imaged using a 10 objective. The number of invaded cells
from three independent experiments were counted.
2.6. Lentiviral delivery of shRNA and LC3 expression vector
The retroviral-based pBABE-mCherry-EGFP-LC3B was a generous
gift from the lab of Dr. Nathan Davis [24] and was originally pur-
chased from Addgene (Cambridge, MA, Plasmid #22418). Mission
Lentivral Transduction Particles with SIRT1 (TRCN0000018981),
Rab7 (TRCN0000007996), or Non-Target shRNA (SHC202V) were
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facturer's protocol (Sigma). Brieﬂy, cells were incubated with
6 mg/mL Polybrene and 10 mL lentivirus for 48 h prior to selection
with puromycin. Stable cell lines were maintained under puromycin
selection and knockdown was assessed by western blot.
2.7. Cell pH and NHE activity assays
Cells were seeded onto custom designed 30 mm chambers
(Bioptechs, Biological Optical Technologies, Butler, PA) equipped
with a heating element. Cells were assayed for cytosolic pH using
BCECF and ratiometric spectrometry as previously described [25].
NHE activity was assayed by incubation in KHH media (140 mM
NaCl, 3 mM KCl, 1 mM MgCl, 1 mM CaCl2 and 20 mM HEPES plus
10 mM glucose, pH 7.4) followed by a 4-min NH4Cl load (KHH in
which 20 mM NaCl is replaced with 20 mM NH4Cl). This was fol-
lowed by a 1 min exposure to minus sodium (choline chloride
substituted for NaCl) after which the pHi response was con-
tinuously monitored for 8 min. After each experiment, the high
Kþ/nigericin technique was used to clamp the pHi to media
standards of known pH in order to obtain a pH calibration. NHE
activity was obtained from the slope of the rapid recovery over the
ﬁrst 30 s and expressed in DpHi/Dtime.
2.8. Lysosome analysis
Analysis of lysosome positioning relative to the nucleus border
was achieved using the LysoTracker software, a generous gift from
Meiyappan Solaiyappan at Johns Hopkins University. Twenty-ﬁve
representative cells from three independent experiments were
analyzed for each experimental condition. Error bars represent
SEM. Signiﬁcance was determined using Two-Tailed Mann–-
Whitney t test in GraphPad Software, Prism 3.0.3. Results
3.1. Cambinol prevents acidic pHe-induced anterograde lysosome
trafﬁcking
We previously reported that acidic pHe drives anterograde lyso-
some trafﬁcking and that certain drugs induce JLA that inhibits tumor
cell invasion [10–13]. Some of these drugs were shown to activate
Rab7. Our collaborators have shown that cells treated with the SIRT1/
2 inhibitor, cambinol, exhibited increased Rab7 mRNA expression
(unpublished microarray data). Because Rab7 is involved in altering
lysosome positioning, we investigated whether cambinol treatment
modulated the position of lysosomes within tumor cells. DU145
prostate cancer cells were pretreated with vehicle or cambinol for six
hours at pH 7.4 followed by exposure to acidic media (pH 6.4) for two
hours in the continued presence of vehicle or drug. Treatment with
acidic media serves to drive anterograde lysosome trafﬁcking [12].
Lysosomes were visualized by immunoﬂuorescence microscopy of
Lysosome Associated Membrane Protein-1 (LAMP-1) (Fig. 1A).
Quantitation of LAMP-1 positive vesicles (red) revealed that acidic
pHe caused a peripheral lysosome distribution relative to neutral pH
(compare Fig. 1AI and AII) and that cambinol-treated cells displayed
signiﬁcant JLA when compared to cells treated with acidic media
alone (compare Fig. 1 AII with Fig. 1 AIII; quantitated in Fig. 1B). Si-
milar results were observed in the glioma cell line A172 and the
prostate cancer cell line PPC1 where cambinol treatment caused JLA
(Fig. S1A). Additionally, we treated DU145 (Fig. 1C), PPC1, and A172
cells (Fig. S1B) with cambinol over time and probed for levels of
LAMP-1 protein by western blot. We found no change in total LAMP-
1 levels upon cambinol treatment, supporting the hypothesis that
cambinol is causing lysosome aggregation, rather than exocytosis,resulting in a loss of LAMP-1. Collectively, these data suggest that the
effects of cambinol on lysosome distribution are not cell line or tis-
sue-type speciﬁc and is not the result of rapid lysosome exocytosis.
Furthermore, we pre-treated DU145 cells with pH 6.4 media for 48 h
prior to the addition of cambinol and found that cambinol treatment
reverses acidic pHe-mediated anterograde lysosome trafﬁcking (Fig.
S1C). Additionally, Transwell invasion assays revealed that cambinol
treatment prevented acidic pHe-mediated invasion of DU145 cells
(Fig. 1D), consistent with previous studies showing that inhibition of
lysosome trafﬁcking blocks tumor cell invasion [10–13].
Next, we asked whether cambinol treatment caused alteration in
the intracellular position of other organelles. DU145 prostate cancer
cells were pretreated with vehicle or cambinol for six hours at pH
7.4 followed by exposure to acidic media (pH 6.4) for two hours in
the continued presence of vehicle or drug. Cells were then ﬁxed and
stained for early endosomes (EEA1), cis-Golgi (GM130). Mitochon-
dria were visualized by loading Mitotracker into live cells prior to
ﬁxation. Interestingly, cells treated with cambinol also displayed
altered distribution of cis-Golgi and mitochondria compared to cells
exposed to acidic pHe alone (Fig. S1D). Cambinol treated DU145
prostate cancer cells showed a reduction in the nuclear localized
clusters of GM130-positive vesicles (white arrows), and mitochon-
dria appeared disordered, rather than localized in ﬁbrous tracks
(white arrows). Although the location of these organelles was not as
drastically altered as lysosomes, the disorganized state of cis-Golgi
and mitochondria in cambinol treated cells suggests that cambinol
may be disrupting global organelle trafﬁcking or cytoskeleton dy-
namics within the cell. To test the possibility of altered cytoskeletal
dynamics, we incubated cells with cambinol or vehicle control for
six hours at pH 7.4 followed by exposure to acidic media (pH 6.4) for
two hours in the presence or absence of cambinol and then stained
for α-tubulin or F-actin (Fig. 1E). Vehicle treated cells exhibited
robust α-tubulin staining and intense F-actin staining with the
appearance of many stress ﬁbers. However, the α-tubulin staining
in cells treated with cambinol revealed fewer microtubules, which
may indicate reduced microtubule stability. Additionally, cambinol
treatment resulted in a loss of stress ﬁbers and an overall reduction
in F-actin intensity. These data are consistent with the possibility
that cambinol treatment disrupts cytoskeletal dynamics, which may
contribute to the altered organelle trafﬁcking.
3.2. Rab7 is not required for cambinol-induced JLA
Previous studies showed that the lysosome localized GTPase
Rab7 was necessary for an anti-diabetic agent, Tro, to induce JLA
[10,11]. Rab7 is known to engage dynein motors to facilitate in-
ward movement of lysosomes. Due to the association between
sirtuin inhibition and upregulation of Rab7 transcript levels (un-
published microarray data), we tested whether Rab7 was also
necessary for cambinol mediated JLA. Cells were stably transduced
with lentiviral-delivered shRNA to Rab7 and depletion of Rab7
protein compared to NonTarget shRNA cells was conﬁrmed by
western blot analysis (Fig. 2A). This level of Rab7 knockdown was
sufﬁcient to block Tro-mediated JLA [10,11]. These cells were then
treated with cambinol or vehicle for 6 h in pH 7.4 media. Treat-
ment with acidic media was not used because Rab7 expressing
cells already have lysosomes localized toward the periphery. Im-
munoﬂuorescence microscopy to detect LAMP-1 positive vesicles
(red) revealed that cambinol induced JLA in both the Non-Target
and Rab7 shRNA expressing cells (Fig. 2B and C). These unexpected
results demonstrate that Rab7 is not necessary for the JLA induced
by cambinol treatment and that cambinol induces JLA by a me-
chanism different from Tro. Finally, in contrast to microarray data,
no increase in Rab7 protein levels was observed in cells treated
with cambinol (data not shown), consistent with cambinol altering
lysosome positioning independent of Rab7 activity.
Fig. 2. Cambinol induces juxtanuclear lysosome aggregation independent of Rab7. (A) DU145 prostate cancer cells were transduced with lentiviral delivered shRNA against
Rab7. Western blot analysis indicates that Rab7 is depleted. (B) DU145 NonTarget (NT) shRNA expressing cells or Rab7 shRNA expressing cells were treated with vehicle or
50 mM cambinol for 6 h at pH 7.4. Cells were ﬁxed and stained for LAMP-1 (red), phalloidin (green), and DAPI (blue) (N¼3). Scale bar represents 50 mm. (C) Represents mean
lysosome distribution for 25 cells spanning 3 independent experiments. Error bars represent SEM. *po0.0001 compared to NonTarget DMSO.
Fig. 3. Cambinol-induced juxtanuclear lysosome aggregation is independent of gene expression changes. (A) DU145 cells were treated with vehicle or 50 mM cambinol for a
range of time at pH 7.4 followed by treatment for two hours at pH 6.4 plus drug (top panel). Cells were treated with increasing concentrations of cambinol for 6 h at pH
7.4 followed by 2 h treatment at pH 6.4 plus drug (bottom panel) Cells were ﬁxed and stained with LAMP-1 (red), phalloidin (green), and DAPI (blue) (N¼3). (B) DU145 were
treated with vehicle or 50 mM cambinol in the presence or absence of 10 mM Actinomycin D for 6 h at pH 7.4 followed by a 2 h treatment at pH 6.4 plus drug. Cells were ﬁxed
and stained for LAMP-1 (red), phalloidin (green), and DAPI (blue) (N¼3). Scale bars represent 50 mm. (C) Represents mean lysosome distribution for 25 cells spanning
3 independent experiments. Error bars represent SEM. *po0.0001 compared to pH 6.4 and #po0.0001 compared to Actinomycin D.
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ated JLA
Tro and the NHE inhibitor EIPA, require a 16 h treatment period
before a JLA phenotype is observed [10,13]. This long time frame
suggests that changes in gene expression may be necessary for
EIPA and Tro to affect lysosome positioning. To test this, DU145
prostate cancer cells were treated with 10 μM Tro in the presence
or absence of the mRNA synthesis inhibitor, Actinomycin D (Fig.
S2). Tro treatment did not cause JLA in the presence of Actino-
mycin D, suggesting that changes in gene expression are critical to
the mechanism of action of Tro. In order to assess the time frame
and minimum concentration of cambinol needed for JLA, DU145
prostate cancer cells were treated with 50 μM cambinol forFig. 4. Cambinol-induced juxtanuclear lysosome aggregation is independent of SIRT1/SI
SIRT1. Western blot analysis indicates that SIRT1 protein levels are reduced in cells expr
expressing DU145 were treated with vehicle or 50 mM cambinol, 3 mM EX527, or 10 mM A
Cells were ﬁxed and stained for LAMP-1 (red), phalloidin (green), and DAPI (blue) (N¼
experiments. Error bars represent SEM. *po0.0001 compared to NT control and #po0varying amounts of time (top panel) or varying does of cambinol
for 6 h at pH 7.4 followed by a two hour incubation in pH
6.4 media plus drug (bottom panel) (Fig. 3A). We found that
cambinol induced JLA in as little as 4 h post-treatment at a con-
centration of 50 mM and JLA was complete within 8 h of treatment
(6 h pH 7.4, 2 h pH 6.4) at concentrations above 25 μM. This short
time frame in which cambinol acted suggests that this drug is
acting independently of changes in gene expression. Therefore, we
then treated cells with cambinol in the presence or absence of
Actinomycin D (Fig. 3B and C). Cambinol treatment still resulted in
JLA even when transcription was inhibited by Actinomycin D. Ta-
ken together, these results supports the hypothesis that unlike Tro,
cambinol-induced JLA is independent of gene expression changes.RT2 inhibition. (A) DU145 were transduced with lentiviral delivered shRNA against
essing SIRT1 shRNA compared to NonTarget shRNA. (B) NonTarget or SIRT1 shRNA
GK2 for 6 h in pH 7.4 followed by a 2 h treatment in the presence of drugs at pH 6.4.
3). (C) Represents mean lysosome distribution of 25 cells spanning 3 independent
.0004 compared to SIRT1 KD control.
Fig. 5. MAP Kinase signaling is necessary for cambinol-induced juxtanuclear lysosome aggregation. (A) DU145 cells were treated with 50 mM cambinol over time. Whole cell
lysates were harvested and levels of total MAPK and activated MAPK were analyzed by western blot (N¼3). (B) Cells were treated with the MAPK inhibitor, 10 mM UO126, or
50 mM cambinol for 6 h in pH 7.4, followed by a 2 h treatment in pH 6.4 plus drug. Cells were ﬁxed and stained for LAMP-1 (red), phalloidin (green), and DAPI, (blue) (N¼3).
Scale bar represents 50 mm. (C) Represents mean lysosome distribution of 25 cells spanning 3 independent experiments. Error bars represent SEM and *p40.0001 compared
to DMSO control. (D) DU145 cells were treated with the MAPK inhibitor, 10 mM UO126, or 50 mM cambinol for 6 h in pH 7.4, followed by a 2 h treatment in pH 6.4 plus drug.
Cells were ﬁxed and stained for α-tubulin (N¼3). Scale bar represents 50 mm.
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The signiﬁcant change in mean lysosome distance from the
nucleus observed in cambinol treated cells led us to investigate
the mechanism by which this drug causes perinuclear lysosome
clustering. We hypothesized that cambinol induced lysosome re-
distribution by inhibiting SIRT1 or SIRT2 activity, and that the
absence of sirtuin activity would result in JLA [21]. To test this
hypothesis, we treated DU145 prostate cancer cells with lentiviral-
delivered shRNA and depleted SIRT1 protein levels by more than
85% as determined by western blot analysis (Fig. 4A). We then
treated SIRT1 knockdown or NonTarget cells with vehicle control
for 6 h at pH 7.4 followed by a two hour treatment at pH 6.4. SIRT1
knockdown cells still underwent anterograde lysosome trafﬁcking
in response to acidic pHe similar to NonTarget control cells, sug-
gesting that loss of SIRT1 is not sufﬁcient to prevent acidic pHe
driven lysosome redistribution (Fig. 4B and C). SIRT1 and SIRT2 are
reported to have some overlapping targets, most notably,members of the forkhead box O (FOXO) family of transcription
factors [26,27]. We were unable to generate KDs of SIRT1 and
SIRT2, therefore, we used speciﬁc inhibitors that target either
SIRT1 (EX527) or SIRT2 (AGK2) [28,29]. The highest non-toxic
concentration of inhibitors was used. NonTarget and SIRT1
knockdown cells were treated for 6 h with cambinol, EX527 and
AGK2 alone or in combination, or with vehicle control and then
exposed to 2 h of acidic pHe (to induce lysosome movement) in the
presence of the speciﬁed drug. Cells were ﬁxed and stained for
LAMP-1 (red). LAMP-1-positive vesicles were still found to redis-
tribute to the plasma membrane in response to acidic pHe even in
the presence of duel SIRT1 and SIRT2 inhibition (Fig. 4B and C).
These data suggest that SIRT1 and/or SIRT2 activity is not neces-
sary for anterograde lysosome trafﬁcking. To investigate the pos-
sible role of other HDACs in anterograde lysosome trafﬁcking, we
examined lysosomal localization in cells treated with two HDAC
inhibitors, nicotinomide and trichostatin A (TSA). Nicotinamide is
a byproduct of the NADþ dependent-deacetylation reaction and
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TSA is an inhibitor of class I and class II HDACs [32]. DU145 cells
were treated with vehicle, nicotinomide, or TSA for 6 h in pH
7.4 and then moved to acidic media (pH 6.4) containing the same
treatment for an additional 2 h. LAMP-1 staining showed that ly-
sosomes in cells treated with nicotinomide or TSAwere positioned
throughout the cell, similar to vehicle-treated cells (Fig. S3A). As a
control to show that these inhibitors were working, DU145 cells
were treated with the afore mentioned sirtuin inhibitors and le-
vels of acetylated tubulin (Fig. S3B) or acetylated p53 (Fig. S3C)
were detected by western blot. Collectively, these data indicate
that cambinol treatment prevents anterograde lysosome trafﬁck-
ing independent of its role as an HDAC inhibitor and that HDAC
inhibition alone is not sufﬁcient to drive JLA.
3.5. Cambinol treatment does not inhibit sodium proton exchanger
activity
Lysosomes trafﬁc toward the plasma membrane in response to
decreased cytosolic pH [12,14]. This cytosolic pH is regulated, in
part, by the activity of NHEs. As such, NHE inhibitors reverse
anterograde lysosome trafﬁcking. We previously characterized Tro
as a potent inhibitor of NHE activity, which in turn drives JLA [10–
13]. We wondered whether cambinol, like Tro, also inhibited NHE
activity. To test this, NHE activity and cytosolic pH were measured
in the presence or absence of cambinol (Fig. S4). Exchanger activity
was not decreased in cambinol treated cells compared to control.
This indicates that cambinol is not acting as an NHE inhibitor and
is in fact causing JLA by a mechanism different from that med-
iating the effect of Tro.
3.6. ERK1/2 activity is necessary for cambinol-induced JLA
Retrograde lysosomal transport is regulated in part by the
ORP1L/RILP/dynein complex, and ERK1/2 plays a role in the as-
sembly of this complex [33]. Tro treatment results in the activation
of ERK1/2 signaling, which this is necessary for JLA [10]. To in-
vestigate whether cambinol modulates ERK1/2 activity, cells were
treated with 50 μM cambinol for different lengths of time span-
ning 24 h and levels of phosphorylated (active) and total ERK1/2
were determined by western blotting (Fig. 5A). Cambinol treat-
ment induced a robust activation of ERK1/2 at one hour post-
treatment, and this activity was sustained until 12 h post-treat-
ment. We found no change in levels of total ERK1/2 protein. Ad-
ditionally, cambinol treatment caused activation of MEK1/2, the
upstream mitogen activated protein kinase that is responsible for
ERK1/2 activation (Fig. S5) [34]. To elucidate the role of ERK1/2
activity in cambinol-mediated JLA, cells were treated at pH
7.4 with cambinol in the presence or absence of the ERK1/2 spe-
ciﬁc inhibitor U0126 for six hours followed by a two hour treat-
ment with acidic pHe (pH 6.4) plus drug (Fig. 5B). Cells were then
ﬁxed, stained with LAMP-1 (red), phalloidin (green) and DAPI
(blue) and assessed for lysosome positioning. Control treated cells
displayed lysosomes located close to the cell periphery, while cells
treated with cambinol alone showed lysosomes clustered near the
nucleus. However, cells treated with cambinol in the presence of
the ERK1/2 inhibitor U0126 did not show lysosome aggregation
and instead had lysosomes diffuse throughout the cell (Fig. 5B and
C), suggesting that ERK1/2 activity is necessary for cambinol
mediated JLA. Cambinol treatment resulted in reduced cytoskele-
ton integrity (Fig. 1E), which may partially account for the JLA
phenotype. ERK1/2 is known to associate with microtubules and to
inﬂuence microtubule stability [35]. We asked whether this MAPK
pathway regulated cambinol-mediated cytoskeletal changes. To
test this, DU145 cells were treated with cambinol or U0126 at pH
7.4 for six hours followed by a two hour treatment with acidic pHe(pH 6.4) plus drug (Fig. 5D). Immunoﬂuorescence microscopy of α-
tubulin revealed that inhibition of ERK1/2 partially prevented
cambinol-mediated microtubule loss. Collectively, these data im-
ply that cambinol is disrupting organelle trafﬁcking via an ERK1/2-
mediated microtubule disruption.
3.7. Cambinol-induced JLA is not a result of autophagy induction
Nutrient starvation can lead to the activation of autophagy, a
catabolic process that delivers cytoplasmic contents to the lysosome
for degradation (reviewed in [36]). Autophagy is controlled by
mammalian target of Rapamycin (mTOR), which inhibits autophagy
under permissive growth conditions. The induction of autophagy
causes the formation of membrane-bound autophagosomes which
fuse with lysosomes in the juxtanuclear region to form autopha-
golysosomes, leading to an accumulation of these LAMP-1-positive
vesicles in the perinuclear space [37]. Autophagy can be regulated
by MEK/ERK1/2 signaling [38], and because cambinol requires
ERK1/2 activation for JLA (Fig. 5), we investigated whether cambinol
treatment activated autophagy. To test whether cambinol inﬂu-
enced the activity of the mTOR pathway, DU145 prostate cancer
cells were treated with 50 μM cambinol over an 8 h time course. As
a positive control for induction of autophagy cells were treated with
Rapamycin for 8 h. Whole cell lysates were collected and probed for
phospho-S6 kinase, a mitogen-activated serine/threonine kinase
downstream of mTOR, by western blot (Fig. 6A). Rapamycin treat-
ment activated autophagy as indicated by the loss of p70 S6 kinase
phosphorylation. However, p70 S6 kinase was not depho-
sphorylated under conditions of cambinol treatment, suggesting
that cambinol does not activate the autophagy pathway via mTOR
inhibition. Additionally, cambinol treatment did not lead to the
appearance of Light Chain 3 II (LC3II) as seen with Rapamycin
treatment (Fig. 6B). For further conformation, DU145 prostate can-
cer cells were generated to stably express GFP and mCherry tagged
LC3, a marker of autophagosome and autophagolysosome mem-
branes [39]. Cells were then treated with vehicle, 50 μM cambinol,
or 1 μM Rapamycin for 6 h at pH 7.4 followed by a 2 h treatment in
pH 6.4 media plus drug. Immunoﬂuorescence microscopy revealed
that Rapamycin treatment caused perinuclear aggregation of GFP
and mCherry tagged LC3, but vehicle or cambinol treatment did not
(Fig. 6C). Collectively, these data imply that cambinol is not acti-
vating the autophagy pathway as a mechanism for JLA.4. Discussion
In the present study we identify cambinol, a sirtuin inhibitor, as
a potent regulator of lysosome trafﬁcking and inducer of JLA.
Cambinol stimulates JLA independently from Rab7, NHE inhibition
or gene expression changes, indicating that cambinol acts to ag-
gregate lysosomes by a mechanism that is highly distinct from that
of Tro. Additionally, cambinol does not activate autophagy as a
means to drive JLA and sirtuin inhibition alone is not sufﬁcient to
drive JLA. We found that cambinol treatment, similar to Tro, does
activate ERK, which is required for JLA.
The peripheral trafﬁcking of juxtanuclear localized lysosomes
in response to microenvironment stimuli results in the enhanced
invasion of tumor cells [10–13]. This anterograde lysosome traf-
ﬁcking movement facilitates the release of lysosomal proteases,
such as cathepsin B, which degrade the surrounding matrix al-
lowing for cell invasion. Increased cathepsin B expression is as-
sociated with invasive cancers and several studies have shown
that inhibiting cathepsin B greatly reduces invasion and metastasis
in vitro and in vivo [3–5,40–42]. Despite the well-characterized
role of cathepsins and other proteases such as MMPs in tumor
invasion, protease inhibitors have repeatedly failed clinical trials
Fig. 6. Cambinol treatment does not induce autophagy. (A) DU145 cells were
treated with 50 mM cambinol over time or 1 mM Rapamycin for 8 h. Whole cell
lysates were collected and probed for the indicated proteins by western blot (N¼3).
(B) DU145 cells were treated with 50 mM cambinol over time or 1 mM Rapamycin
for 8 h. Whole cell lysates were collected and probed for the indicated proteins by
western blot. (C) DU145 prostate cells were made to express LC3-GFP-mcherry.
Cells were treated with vehicle, 50 mM cambinol, or 1 mM Rapamycin for 6 h in pH
7.4, followed by a 2 h treatment in pH 6.4 plus drug. Cells were ﬁxed in methanol
and stained with DAPI. Representative 60X images are shown, N¼3. * represents
cells included in split channel panel.
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novel modality of preventing protease release from the cell might
prove to be more therapeutically successful. To that end, we are
seeking to identify compounds that are novel inhibitors of ante-
rograde lysosome trafﬁcking and predict they will inhibit tumor
cell invasion and subsequent metastasis.
We found the sirtuin inhibitor cambinol to be a potent inhibitor
of acidic pHe-stimulated lysosome trafﬁcking and this effect to be
independent of Rab7, which is in contrast to Rab7-mediated JLA
induced by Tro (Figs. 1 and 2). Our laboratory has previously de-
tailed the ability of Tro to initiate a JLA phenotype in an ERK/Rab7/
RILP-dependent manner; however, several reports have demon-
strated an unsatisfactory toxicity proﬁle for this agent [10]. A un-
ique mechanism of action to induce JLA may overcome the toxicity
reported for Tro. Based on the differences reported here for the
time post-treatment required for JLA, and the sensitivity of JLA
induction to Actinomycin D treatment, we conclude that the me-
chanisms of Tro and cambinol are highly distinct.
In addition to their role in histone de-acetylation and control of
transcription, SIRT1 and SIRT2 also de-acetylate many non-histone
targets. Acetylation of a positively charged lysine can alter protein
structure, prevent ubiquitination, and inﬂuence afﬁnity to binding
partners (reviewed in [44]). It is possible that cambinol treatment
inﬂuences the acetylation and activity of proteins known to be
involved in lysosome movement. Of note, Sirtuins are reported to
deacetylate major cytoskeletal components such as tubulin and
cortactin, a known regulator of actin polymerization [45,46]. Ly-
sosomes and other organelles are trafﬁcked along microtubules
and actin ﬁlaments through the action of kinesin and dynein
motors, and lysosomes can be found in cortactin-rich invadopodia
[6,8]. Interestingly, we did observe that microtubules and F-actin
organization was altered in cambinol-treated cells (Fig. 1D). This
altered cytoskeletal arrangement may be at least partially re-
sponsible for the lysosome clustering seen upon cambinol treat-
ment. However, we found that Sirtuin1 knockdown or pharma-
cological inhibition of both SIRT1 and SIRT2 did not induce JLA
(Fig. 4B and C), suggesting that any organelle trafﬁcking or cy-
toskeletal defects with cambinol treatment may be independent
from its activity as a SIRT1/2 inhibitor. While speciﬁc HDACs are
known to facilitate organelle trafﬁcking [47], the data presented
herein suggest that, in general, HDACs do not play a role in acidic
pHe-mediated lysosome trafﬁcking. We conclude that the JLA seen
with cambinol treatment is most likely due to an as-yet uni-
dentiﬁed pathway altered by the drug treatment. We are not the
ﬁrst to report that cambinol has ‘off target’ effects. The Roger lab
recently reported that cambinol and sirtinol treatment blocked
cytokine production in macrophages independently of SIRT1/2
inhibition [48].
Tro activates the MAPK pathway and ERK 1/2 activation is ne-
cessary for Tro-mediated lysosome clustering [10]. Similarly,
cambinol also activated ERK 1/2 and this activation is necessary for
cambinol-mediated JLA. This ﬁnding is in contrast to previous
reports from the Roger and Liu lab's that cambinol treatment or
SIRT1 inhibition results in decreased ERK1/2 phosphorylation
[48,49]. The discrepancies between our ﬁndings and previously
published results may be explained by varying cell lines and
concentrations/timeframes of cambinol treatment. ERK1/2 can
localize to and signal from late endosomes and lysosome mem-
branes and lysosome-localized ERK1/2 is thought to aid in the
activation and/or recruitment of the Rab7/RILP/Dynein complex
[50,51]. However, our data indicates that cambinol can cause JLA
independently of Rab7 (Fig. 2), suggesting that ERK1/2-mediated
regulation of Rab7/RILP/Dynein is not the mechanism by which
cambinol triggers lysosome clustering. Several studies report that
ERK1/2 activity is necessary for the formation of mature autop-
hagolysosomes, which are starvation induced LAMP-1 positive
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However, our data suggests that cambinol treatment is not sti-
mulating autophagy (Fig. 6), and that cambinol-induced JLA is not
a result of autophagolysosome formation. However, we did ﬁnd
that ERK1/2 inhibition abrogated cambinol's effects on the mi-
crotubule network (Fig. 5D). As lysosomes and other organellese
trafﬁc along microtubules, this ERK1/2-mediated cytoskeletal
disruption is most likely the mechanism by which cambinol in-
duces JLA. The precise molecular mechanisms by which cambinol
activates MEK1/2 and ERK1/2 remain to be determined.
Both sirtuins and peripheral lysosome trafﬁcking contribute to
tumor progression. Due to drug resistance, multimodality cancer
treatments are gaining traction and it may be beneﬁcial to target
lysosome trafﬁcking in addition to sirtuin inhibition. Currently there
are several HDAC inhibitors in clinical trials as anti-cancer drugs
[54]. Although we have shown that cambinol does indeed induce
JLA and this drug is reported to inhibit tumor invasion in vitro and
in vivo, cambinol may not be marketable for clinical applications
due to these unknown ‘off target’ properties [21]. Tro also prevents
anterograde lysosome trafﬁcking, but Tro and many other thiazo-
lidendione family drugs have been removed from the clinic due to
toxicity. Although Tro and cambinol may not be ideal for use in a
clinical setting, the study of the mechanisms by which these drugs
redistribute lysosomes will contribute to our overall understanding
of the molecular mechanisms that govern lysosome trafﬁcking.
Therefore, future studies aim to identify the precise mechanism by
which cambinol and Tro trigger JLA. Additionally, we plan to in-
vestigate novel compounds that prevent anterograde lysosome
trafﬁcking, similar to that of Tro and cambinol, and their role in
inhibiting tumor invasion. Finally, it would be interesting to test
cambinol in combination with other lysosome trafﬁcking inhibitors
to determine if it will enhance effectiveness of antitumor therapies.Conﬂict of interest
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